↓ Skip to main content

Removal of Hepatitis C Virus-Infected Cells by a Zymogenized Bacterial Toxin

Overview of attention for article published in PLOS ONE, February 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
1 X user
patent
3 patents
facebook
2 Facebook pages

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Removal of Hepatitis C Virus-Infected Cells by a Zymogenized Bacterial Toxin
Published in
PLOS ONE, February 2012
DOI 10.1371/journal.pone.0032320
Pubmed ID
Authors

Assaf Shapira, Shiran Shapira, Meital Gal-Tanamy, Romy Zemel, Ran Tur-Kaspa, Itai Benhar

Abstract

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and has become a global health threat. No HCV vaccine is currently available and treatment with antiviral therapy is associated with adverse side effects. Moreover, there is no preventive therapy for recurrent hepatitis C post liver transplantation. The NS3 serine protease is necessary for HCV replication and represents a prime target for developing anti HCV therapies. Recently we described a therapeutic approach for eradication of HCV infected cells that is based on protein delivery of two NS3 protease-activatable recombinant toxins we named "zymoxins". These toxins were inactivated by fusion to rationally designed inhibitory peptides via NS3-cleavable linkers. Once delivered to cells where NS3 protease is present, the inhibitory peptide is removed resulting in re-activation of cytotoxic activity. The zymoxins we described suffered from two limitations: they required high levels of protease for activation and had basal activities in the un-activated form that resulted in a narrow potential therapeutic window. Here, we present a solution that overcame the major limitations of the "first generation zymoxins" by converting MazF ribonuclease, the toxic component of the E. coli chromosomal MazEF toxin-antitoxin system, into an NS3-activated zymoxin that is introduced to cells by means of gene delivery. We constructed an expression cassette that encodes for a single polypeptide that incorporates both the toxin and a fragment of its potent natural antidote, MazE, linked via an NS3-cleavable linker. While covalently paired to its inhibitor, the ribonuclease is well tolerated when expressed in naïve, healthy cells. In contrast, activating proteolysis that is induced by even low levels of NS3, results in an eradication of NS3 expressing model cells and HCV infected cells. Zymoxins may thus become a valuable tool in eradicating cells infected by intracellular pathogens that express intracellular proteases.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 2%
Denmark 1 2%
Canada 1 2%
Unknown 45 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 27%
Researcher 9 19%
Student > Bachelor 5 10%
Student > Master 4 8%
Professor > Associate Professor 3 6%
Other 6 13%
Unknown 8 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 40%
Biochemistry, Genetics and Molecular Biology 11 23%
Medicine and Dentistry 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Immunology and Microbiology 2 4%
Other 3 6%
Unknown 6 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2021.
All research outputs
#4,285,591
of 23,577,761 outputs
Outputs from PLOS ONE
#64,835
of 202,084 outputs
Outputs of similar age
#26,879
of 156,558 outputs
Outputs of similar age from PLOS ONE
#728
of 3,549 outputs
Altmetric has tracked 23,577,761 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 202,084 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,558 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 3,549 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.